Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120

被引:29
作者
Berkower, I [1 ]
Raymond, M [1 ]
Muller, J [1 ]
Spadaccini, A [1 ]
Aberdeen, A [1 ]
机构
[1] Off Vaccine Res & Review, Ctr Biol, Div Viral Prod, Lab Immunoregulat, Bethesda, MD 20892 USA
关键词
virus-like particles; HIV-1; envelope glycoprotein gp120;
D O I
10.1016/j.virol.2003.12.017
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In order to improve the immunogenicity of HIV-1 envelope glycoproteins, we have fused gp120 to a carrier protein, hepatitis B surface antigen (HBsAg), which is capable of spontaneous assembly into virus-like particles. The HBsAg-gp120 hybrid proteins assembled efficiently into 20-30 nm particles. The particles resemble native HBsAg particles in size and density, consistent with a lipid composition of about 25% and a gp120 content of about 100 per particle. Particulate gp120 folds in its native conformation and is biologically active, as shown by high affinity binding of CD4. The particles express conformational determinants targeted by a panel of broadly cross-reactive neutralizing antibodies, and they show tight packing of gp120. Because the particles are lipoprotein micelles, an array of gp120 on their surface closely mimics gp120 on the surface of HIV-1 virions. These gp120-rich particles can enhance the quality, as well as quantity, of antibodies elicited by a gp120 vaccine. Published by Elsevier Inc.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 63 条
[1]   ELECTRON-MICROSCOPIC AND SOLUTION X-RAY-SCATTERING OBSERVATIONS ON THE STRUCTURE OF HEPATITIS-B SURFACE-ANTIGEN [J].
AGGERBECK, LP ;
PETERSON, DL .
VIROLOGY, 1985, 141 (01) :155-161
[2]  
Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311
[3]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[4]   Neutralizing antiviral B cell responses [J].
Bachmann, MF ;
Zinkernagel, RM .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :235-270
[5]   CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1 [J].
Berkower, I ;
Mostowski, H ;
Bull, TE ;
Murphy, D .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) :863-869
[6]   A PREDOMINANT GROUP-SPECIFIC NEUTRALIZING EPITOPE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MAPS TO RESIDUE-342 TO RESIDUE-511 OF THE ENVELOPE GLYCOPROTEIN-GP120 [J].
BERKOWER, I ;
MURPHY, D ;
SMITH, CC ;
SMITH, GE .
JOURNAL OF VIROLOGY, 1991, 65 (11) :5983-5990
[7]   HUMAN IMMUNODEFICIENCY VIRUS-1 - PREDOMINANCE OF A GROUP-SPECIFIC NEUTRALIZING EPITOPE THAT PERSISTS DESPITE GENETIC-VARIATION [J].
BERKOWER, I ;
SMITH, GE ;
GIRI, C ;
MURPHY, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (05) :1681-1695
[8]   Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen [J].
Bisht, H ;
Chugh, DA ;
Raje, M ;
Swaminathan, S ;
Khanna, N .
JOURNAL OF BIOTECHNOLOGY, 2002, 99 (02) :97-110
[9]   MUTATIONAL ANALYSIS OF HEPATITIS-B SURFACE-ANTIGEN PARTICLE ASSEMBLY AND SECRETION [J].
BRUSS, V ;
GANEM, D .
JOURNAL OF VIROLOGY, 1991, 65 (07) :3813-3820
[10]  
BUCHACHER A, 1992, VACCINES, V92, P191